From the National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.
From the National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.
Am J Ophthalmol. 2023 Sep;253:224-232. doi: 10.1016/j.ajo.2023.05.014. Epub 2023 May 20.
To systematically assess the ability to detect change and retest reliability for a panel of visual function assessments in ABCA4 retinopathy.
Prospective natural history study (NCT01736293).
Patients with at least 1 documented pathogenic ABCA4 variant and a clinical phenotype consistent with ABCA4 retinopathy were recruited from a tertiary referral center. Participants underwent longitudinal, multifaceted functional testing, including measures of function at fixation (best-corrected visual acuity, low-vision Cambridge Color Test), macular function (microperimetry), and retina-wide function (full-field electroretinography [ERG]). Two- and 5-year ability to detect change was determined based on the η statistic.
A total of 134 eyes from 67 participants with a mean follow-up of 3.65 years were included. In the 2-year interval, the microperimetry-derived perilesional sensitivity (η of 0.73 [0.53, 0.83]; -1.79 dB/y [-2.2, -1.37]) and mean sensitivity (η of 0.62 [0.38, 0.76]; -1.28 dB/y [-1.67, -0.89]) showed most change over time, but could only be recorded in 71.6% of the participants. In the 5-year interval, the dark-adapted ERG a- and b-wave amplitude showed marked change over time as well (eg, DA 30 a-wave amplitude with an η of 0.54 [0.34, 0.68]; -0.02 log(µV)/y [-0.02, -0.01]). The genotype explained a large fraction of variability in the ERG-based age of disease initiation (adjusted R of 0.73) CONCLUSIONS: Microperimetry-based clinical outcome assessments were most sensitive to change but could only be acquired in a subset of participants. Across a 5-year interval, the ERG DA 30 a-wave amplitude was sensitive to disease progression, potentially allowing for more inclusive clinical trial designs encompassing the whole ABCA4 retinopathy spectrum.
系统评估 ABCA4 视网膜病变中一组视觉功能评估的变化检测能力和重测可靠性。
前瞻性自然史研究(NCT01736293)。
从三级转诊中心招募至少有 1 个记录的致病性 ABCA4 变异和与 ABCA4 视网膜病变一致的临床表型的患者。参与者接受了纵向的、多方面的功能测试,包括注视时的功能测量(最佳矫正视力、低视力剑桥颜色测试)、黄斑功能(微视野计)和视网膜整体功能(全视野视网膜电图 [ERG])。基于 η 统计量确定了 2 年和 5 年的变化检测能力。
共纳入 67 名患者的 134 只眼,平均随访 3.65 年。在 2 年的时间间隔内,微视野计测量的病变周围敏感度(η 为 0.73 [0.53,0.83];-1.79dB/y [-2.2,-1.37])和平均敏感度(η 为 0.62 [0.38,0.76];-1.28dB/y [-1.67,-0.89])显示随时间推移变化最大,但只能在 71.6%的参与者中记录。在 5 年的时间间隔内,暗适应 ERG 的 a 波和 b 波幅度也显示出明显的随时间变化(例如,DA30a 波幅度的 η 为 0.54 [0.34,0.68];-0.02log(µV)/y [-0.02,-0.01])。基因型解释了 ERG 计算的疾病起始年龄的很大一部分变异性(调整后的 R 为 0.73)。
基于微视野计的临床结局评估对变化最敏感,但只能在一部分参与者中获得。在 5 年的时间间隔内,ERG 的 DA30a 波幅度对疾病进展敏感,这可能使更具包容性的临床试验设计涵盖整个 ABCA4 视网膜病变谱。